Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling
Primary Purpose
Alcohol Consumption
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Placebo
10 mg Obeticholic Acid (OCA)
Sponsored by

About this trial
This is an interventional other trial for Alcohol Consumption
Eligibility Criteria
Inclusion Criteria:
- Individuals ≥ 21 to 65 years old
- Able to provide informed consent & negative urine pregnancy test where appropriate
- Healthy controls must have not consumed any alcohol within 3 months prior to the screening visit
- Heavy alcohol drinking is defined as > 40 grams per day on average in women and > 60 grams per day on average in men for a minimum of 6 months
- Women of child bearing potential should be willing to practice contraception throughout the treatment period
Exclusion Criteria:
- Active infection as evidenced by positive urine culture, blood culture, or pneumonia
- Serum creatinine > 1.5 mg/dL
- Known co-existing infection with hepatitis C, hepatitis B, or HIV
- Significant systemic or major illness including COPD, CHF and renal failure that in the opinion of the Investigator would preclude the patient from participating in and completing the study.
- Participation in another investigational drug, biologic, or medical device trial within 30 days prior to Screening
- Previous history of jaundice or signs of liver diseases such as spider angiomata, ascites, or history of esophageal varices or hepatic encephalopathy
- Total bilirubin > 2 mg/dl and INR > 1.5 Page 20 of 37
- Women who are pregnant or nursing
- Presence of any other disease or condition that is interfering with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the intestine. Patients who have undergone gastric bypass procedures will be excluded (gastric lap band is acceptable).
- Subjects who are taking warfarin
Sites / Locations
- Indiana University
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
No Intervention
Arm Label
Placebo
10 mg Obeticholic Acid (OCA)
Non-drinking Controls
Arm Description
Heavy Drinkers on placebo
10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 4 weeks.
Non-drinking healthy controls
Outcomes
Primary Outcome Measures
Change in Bile Salt Metabolism (C4 )Levels to Determine Effect of FXR
Change in FGF19 Levels to Determine Effect of FXR
Secondary Outcome Measures
Change in Fasting Serum Bile Salt Levels
Change in Oxidative Stress Level by Measuring Malondialdehyde
Change in CYP2E1 Activity by Measuring Chlorzoxazone Clearance
Change in Gut Permeability Through Lactulose/Mannitol Test
This is the measurement to quantify two non-metabolized sugar molecules-lactulose and mannitol-to determine the gut permeability
Change in Bacterial Translocation Through Measures of Plasma LPS
Change in Intestinal Inflammation by Measuring Stool Calprotectin
Change in Activation of Innate Immunity Through Measures of TNF-alpha
Change in Bacterial Translocation Through Measures of Serum sCD14
Change in Activation of Innate Immunity Through Measures of IL-6
Change in Activation of Innate Immunity Through Measures of IL-8
Change in Activation of Innate Immunity Through Measures of IL-1
Full Information
NCT ID
NCT02654236
First Posted
January 6, 2016
Last Updated
April 3, 2023
Sponsor
Suthat Liangpunsakul
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA), Intercept Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT02654236
Brief Title
Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling
Official Title
Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
September 2019 (Actual)
Study Completion Date
September 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Suthat Liangpunsakul
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA), Intercept Pharmaceuticals
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The main purpose of this study is to see whether heavy drinking will interfere with a specific pathway, called FXR signaling in the liver. The abnormality of this pathway may lead to liver injury in some patients who drink heavily.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Consumption
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Heavy Drinkers on placebo
Arm Title
10 mg Obeticholic Acid (OCA)
Arm Type
Experimental
Arm Description
10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 4 weeks.
Arm Title
Non-drinking Controls
Arm Type
No Intervention
Arm Description
Non-drinking healthy controls
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
Intervention Type
Drug
Intervention Name(s)
10 mg Obeticholic Acid (OCA)
Intervention Description
10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
Primary Outcome Measure Information:
Title
Change in Bile Salt Metabolism (C4 )Levels to Determine Effect of FXR
Time Frame
Baseline to 28 days
Title
Change in FGF19 Levels to Determine Effect of FXR
Time Frame
Baseline to 28 days
Secondary Outcome Measure Information:
Title
Change in Fasting Serum Bile Salt Levels
Time Frame
Baseline to 28 days
Title
Change in Oxidative Stress Level by Measuring Malondialdehyde
Time Frame
Baseline to 28 days
Title
Change in CYP2E1 Activity by Measuring Chlorzoxazone Clearance
Time Frame
Baseline to 28 days
Title
Change in Gut Permeability Through Lactulose/Mannitol Test
Description
This is the measurement to quantify two non-metabolized sugar molecules-lactulose and mannitol-to determine the gut permeability
Time Frame
Baseline to 28 days
Title
Change in Bacterial Translocation Through Measures of Plasma LPS
Time Frame
Baseline to 28 days
Title
Change in Intestinal Inflammation by Measuring Stool Calprotectin
Time Frame
Baseline to 28 days
Title
Change in Activation of Innate Immunity Through Measures of TNF-alpha
Time Frame
Baseline to 28 days
Title
Change in Bacterial Translocation Through Measures of Serum sCD14
Time Frame
Baseline to 28 days
Title
Change in Activation of Innate Immunity Through Measures of IL-6
Time Frame
Baseline to 28 days
Title
Change in Activation of Innate Immunity Through Measures of IL-8
Time Frame
Baseline to 28 days
Title
Change in Activation of Innate Immunity Through Measures of IL-1
Time Frame
Baseline to 28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Individuals ≥ 21 to 65 years old
Able to provide informed consent & negative urine pregnancy test where appropriate
Healthy controls must have not consumed any alcohol within 3 months prior to the screening visit
Heavy alcohol drinking is defined as > 40 grams per day on average in women and > 60 grams per day on average in men for a minimum of 6 months
Women of child bearing potential should be willing to practice contraception throughout the treatment period
Exclusion Criteria:
Active infection as evidenced by positive urine culture, blood culture, or pneumonia
Serum creatinine > 1.5 mg/dL
Known co-existing infection with hepatitis C, hepatitis B, or HIV
Significant systemic or major illness including COPD, CHF and renal failure that in the opinion of the Investigator would preclude the patient from participating in and completing the study.
Participation in another investigational drug, biologic, or medical device trial within 30 days prior to Screening
Previous history of jaundice or signs of liver diseases such as spider angiomata, ascites, or history of esophageal varices or hepatic encephalopathy
Total bilirubin > 2 mg/dl and INR > 1.5 Page 20 of 37
Women who are pregnant or nursing
Presence of any other disease or condition that is interfering with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the intestine. Patients who have undergone gastric bypass procedures will be excluded (gastric lap band is acceptable).
Subjects who are taking warfarin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Suthat Liangpunsakul, MD
Organizational Affiliation
Indiana University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Indiana University
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling
We'll reach out to this number within 24 hrs